Table II.
Prognostic value of MBTD1 expression for BCR-free survival revealed by Cox proportional hazards model.
| A, Univariate analysis | |||
|---|---|---|---|
| BCR-free survival | |||
| Variable | HR (95%CI) | P-value | |
| Age (≥60 vs. <60) | 1.319 (0.773–2.250) | 0.310 | |
| PSA level (>4 vs. ≤4) | 10.426 (5.309–20.474) | <0.001b | |
| Gleason score (<7 vs. 7 vs. >7) | 3.175 (1.881–5.360) | <0.001b | |
| Clinical stage (I vs. II vs. III vs. IV) | 1.451 (0.822–2.559) | 0.199 | |
| Tumor invasion (T1-T2 vs. T3-T4) | 3.950 (2.226–7.008) | <0.001b | |
| Lymph node metastasis (N0 vs. N1) | 1.879 (1.049–3.365) | 0.034a | |
| Distant metastasis (M0 vs. M1) | 3.536 (0.488–25.641) | 0.212 | |
| MBTD1 expression (low vs. high) | 1.884 (1.072–3.312) | 0.028a | |
| B, Multivariate analysis | |||
| BCR-free survival | |||
| Variable | HR (95%CI) | P-value | |
| Age (≥60 vs. <60) | 1.193 (0.683–2.085) | 0.536 | |
| Lymph node metastasis (N0 vs. N1) | 1.716 (0.951–3.098) | 0.073 | |
| MBTD1 expression (low vs. high) | 1.840 (1.007–3.362) | 0.047a | |
a
P<0.05
b
P<0.01. HR, hazard ratio; CI, confidence interval; MBTD1, malignant brain tumor domain-containing protein 1.